On February 24, 2025 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences (Press release, Revolution Medicines, FEB 24, 2025, View Source [SID1234650479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

TD Cowen 45th Annual Healthcare Conference
Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
Barclays 27th Annual Global Healthcare Conference
Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
2025 Leerink Partners Global Healthcare Conference
Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: View Source Following the live webcasts, replays will be available on the company’s website for at least 14 days.